Star Imaging Path Lab Limited was conceptualized as the high-tech wing of Janta X-Ray Clinic, which was established in 1978. Star Imaging Path Lab Limited is the ONLY diagnostic brand in the private sector across Delhi and NCR with over three decades of expertise in the healthcare domain. The brand’s unique selling propositions are its comprehensive services—offering Radiology, Pathology, Cardiology, and Neurology all under one roof—and its ability to cater to all three segments of the healthcare value chain: Panels, Referrals, and Preventive care.
Star Imaging and Path Lab, an Book Built Issue, amounting to ₹ 69.46 Crores, consisting an Fresh Issue of 39.20 Lakh Shares worth ₹ 55.66 Crores and an Offer for Sale of 9.72 Lakh Shares totaling to ₹ 13.80 Crores. The subscription period for the Star Imaging and Path Lab IPO opens on August 08, 2025, and closes on August 12, 2025. The allotment is expected to be finalized on or about Wednesday, August 13, 2025, and the shares will be listed on the BSE SME with a tentative listing date set on or about Monday, August 18, 2025.
The Share Price Band of Star Imaging and Path Lab IPO is set at ₹ 135 to ₹ 142 per equity share. The Market Capitalisation of the Star Imaging and Path Lab at IPO price of ₹ 142 per equity share will be ₹ 247.36 Crores. The lot size of the IPO is 1,000 shares. Individual investors are required to invest a minimum of 2 lots (2,000 shares), amounting to ₹ 2,84,000.
SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED is the book running lead manager of the Star Imaging and Path Lab, while KFIN TECHNOLOGIES LIMITED is the registrar for the issue. Share India Securities Limited is the Market Maker for Star Imaging and Path Lab IPO.
Star Imaging and Path Lab Limited IPO GMP Today
The Grey Market Premium of Star Imaging and Path Lab IPO is expected to be ₹ 18 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Star Imaging and Path Lab Limited IPO Live Subscription Status Today: Real-Time Update
As of 07:00 PM on 12 August, 2025, the Star Imaging and Path Lab Limited IPO live subscription status shows that the IPO subscribed 5.04 times on its Final Day of subscription period. Check the Star Imaging and Path Lab IPO Live Subscription Status Today at BSE.
Star Imaging and Path Lab IPO Anchor Investors Report
Star Imaging and Path Lab has raised ₹ 18.51 Crores from Anchor Investors at a price of ₹ 142 per shares in consultation of the Book Running Lead Managers. The company allocated 13,04,000 equity shares to the Anchor Investors. Check Full List of Star Imaging and Path Lab Anchor Investor List.
Note:- Equity Shares allotted to Anchor Investors (if any) are allotted from Qualified Institutional Buyers (QIBs) reservation portion.
Note:- The Number of shares offered shown IPO subscription section table is calculated at the lower end of the price band and Number of shares calculated in IPO details table section is calculated at upper end of the price band in case of Book Building Issue, so there can be difference. This is because we assume shares will be issued by the company at upper band as Anchor Investors also subscribe at upper band and shares will be issued at lower band only if in case of undersubscription of IPO.
Note:- Market Maker portion (if any) are not shown separately in subscription table and included in NIIs reservation portion.
Star Imaging and Path Lab Limited Day Wise IPO GMP Trend
|
Date |
IPO Price |
Expected Listing Price |
GMP |
Last Updated |
| 05 August 2025 | ₹ 142 | ₹ 160 | ₹ 18 (12.67%) | 06:00 PM; 05 August 2025 |
Star Imaging and Path Lab Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Star Imaging and Path Lab IPO allotment date is 13 August, 2025, Wednesday. Star Imaging and Path Lab IPO Allotment will be out on 13th August, 2025 and will be live on Registrar Website from the allotment date. Check Star Imaging and Path Lab IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Star Imaging and Path Lab Limited IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Star Imaging and Path Lab Limited IPO
Star Imaging and Path Lab to utilise the Net Proceeds towards the following objects:
1. ₹ 2,500.00 Lakh is required to Meet Working Capital Requirement;
2. ₹ 1,500.00 Lakh is required for Repayment/prepayment of certain borrowings availed of by the Company;
3. ₹ 514.08 Lakh is required for Funding the Capital Expenditure towards purchase of Refurbished Medical Equipment in running facilities
4. General Corporate Expenses
5. Issue Expense
Refer to Star Imaging and Path Lab Limited RHP for more details about the Company.
Check latest IPO Review & analysis, Live IPO GMP today, Live IPO Subscription Status Today, Share Price, Financial Information and other details before applying in the IPO.
The Upcoming IPOs in this week and coming weeks are Star Imaging and Path Lab, Medistep Healthcare, ConnPlex Cinemas, ALL Time Plastics, JSW Cement, Sawaliya Foods Products, ANB Metal Cast.
The Current active IPO are Highway Infrastructure, Parth Electricals & Engineering, Jyoti Global Plast, Essex Marine, Aaradhya Disposal Industries, BLT Logistics, Bhadora Industries, Flysbs Aviation.
The Closed IPOs are Cash Ur Drive Marketing, Renol Polychem, B.D. Industries (Pune), NSDL, Takyon Networks, Mehul Colours, M&B Engineering, Sri Lotus Developers & Realty.
The Recently Listed IPOs which is available for trading in stock Market are Aditya Infotech, Lakshmi India Finance, Kaytex Fabrics, Umiya Mobile, Repono, Shree Refrigerations, Sellowrap Industries, Shanti Gold International, Patel Chem Specialities, Brigade Hotel Ventures, Indiqube Spaces, GNG Electronics, TSC India, Monarch Surveyors & Engineering Consultants, Swastika Castal, Savy Infra, Monika Alcobev, Anthem Biosciences and many more.
Star Imaging and Path Lab IPO Details |
|||||||||||
| IPO Date | August 08, 2025 to August 12, 2025 | ||||||||||
| Listing Date | August 18, 2025 | ||||||||||
| Face Value | ₹ 10.00 | ||||||||||
| Price | ₹ 135 to ₹ 142 per share | ||||||||||
| Lot Size | 1,000 Equity Shares | ||||||||||
| Total Issue Size | 48,92,000 Equity Shares (aggregating to ₹ 69.46 Cr) | ||||||||||
| Fresh Issue | 39,20,000 Equity Shares (aggregating up to ₹ 55.66 Cr) | ||||||||||
| Offer for Sale | 9,72,000 Equity Shares (aggregating to ₹ 13.80 Cr) | ||||||||||
| Issue Type | Book Built Issue | ||||||||||
| Listing At | BSE SME | ||||||||||
| Share holding pre issue | 1,35,00,000 | ||||||||||
| Share holding post issue | 1,74,20,000 | ||||||||||
Star Imaging and Path Lab IPO Lot Size |
|||||||||||
| Application | Lots | Shares | Amount | ||||||||
| Retail (Min) | 2 | 2,000 | ₹2,84,000 | ||||||||
| Retail (Max) | 2 | 2,000 | ₹2,84,000 | ||||||||
| S-HNI (Min) | 3 | 3,000 | ₹4,26,000 | ||||||||
| S-HNI (Max) | 7 | 7,000 | ₹9,94,000 | ||||||||
| B-HNI (Min) | 8 | 8,000 | ₹11,36,000 | ||||||||
Star Imaging and Path Lab IPO Timeline (Tentative Schedule) |
|||||||||||
| IPO Open Date | Friday, 8th August, 2025 | ||||||||||
| IPO Close Date | Tuesday, 12th August, 2025 | ||||||||||
| Basis of Allotment | Wednesday, 13th August, 2025 | ||||||||||
| Initiation of Refunds | Wednesday, 13th August, 2025 | ||||||||||
| Credit of Shares to Demat | Thursday, 14th August, 2025 | ||||||||||
| Listing Date | Monday, 18th August, 2025 | ||||||||||
| Cut-off time for UPI mandate confirmation | 5 PM on 12th August, 2025 | ||||||||||
Star Imaging and Path Lab IPO Reservation |
|||||||||||
| Investor Category | Shares Offered | Reservation % | |||||||||
| QIB Portion | 8,71,000 | Not More than 50% of the Net Issue | |||||||||
| Non-Institutional Investor Portion | 6,57,000 | Not Less than 15% of the Net Issue | |||||||||
| Retail Shares Offered | 15,28,000 | Not Less than 35% of the Net Issue | |||||||||
| Market Maker Portion | 4,80,000 | 9.81% of the Issue | |||||||||
| Employee Reservation | 52,000 | - | |||||||||
| Anchor Investor Portion | 13,04,000 | Allotted from QIB Portion | |||||||||
Star Imaging and Path Lab IPO Promoter Holding |
|||||||||||
| Share Holding Pre Issue | 100.00 % | ||||||||||
| Share Holding Post Issue | 71.92 % | ||||||||||
Star Imaging and Path Lab IPO Subscription Status |
|||||||||||
| Investor Category | Shares Offered | Shares Bid For | No oF Times Subscribed | ||||||||
| Qualified Institutional Buyers (QIB) | 8,71,000 | 1,11,88,000 | 12.85 | ||||||||
| Non Institutional Investors(NIIS) | 11,37,000 | 33,58,000 | 2.95 | ||||||||
| Retail Individual Investors (RIIs) | 15,28,000 | 35,32,000 | 2.31 | ||||||||
| Employee Reservation | 52,000 | 16,000 | 0.31 | ||||||||
| Total | 35,88,000 | 1,80,94,000 | 5.04 | ||||||||
BUSINESS OVERVIEW
Star Imaging and Path Lab Pvt. Ltd. operates a NABL-accredited diagnostic network offering pathology, radiology, cardiology, and neurology services across Delhi (B2C, B2B, B2G), Uttar Pradesh (B2G), and Nasik (B2G).
Established in 1978 as Janta X-Ray Clinic, the company transitioned to a private limited entity in 2004, integrating advanced diagnostic technologies. In 2011, it acquired the businesses of Janta X-Ray Clinic, Star Imaging & Path Lab, and Star Health Care.
Digital X-Ray (Allengers 525R SR & AGFA CR 85-X)
Mammography (Fujifilm AMULET with tomosynthesis)
CT Scans (GE Optima CT660 & Cardiac CT/CTA)
4D/5D Ultrasound (Samsung 5D V6 with elastography)
Bone Mineral Density (GE DEXA)
OPG (Cone Beam Dental OPG)
Biochemistry, Hematology, Histopathology, Microbiology, Cytopathology, Serology, Immunology
Molecular Diagnostics (GeneXpert, RT-PCR, HLA B27, HPV, Viral Load Tests)
Specialized Testing (FNAC, HPLC, Immunoassays, KOH, MGIT)
ECG (GE MAC 400), Stress TMT, ECHO
Holter Monitoring (SEER™ 1000)
EEG (NeuroMax series), EMG, NCV, BERA, VEP
Sleep Study (Polysomnography)
PFT (RMS Helios 401)
FibroScan (LSM by VCTE™, CAP™)
Uroflowmetry
Operates 4 B2C centres in Delhi, with a hub at Tilak Nagar offering full-suite diagnostics.
Runs 19 centres under Public-Private Partnerships (PPP) in Delhi, Uttar Pradesh, and Nashik, totaling 23 centres as of September 30, 2024.
B2B partnerships with 40 empanelled private hospitals (Delhi), offering diagnostics at discounted rates under MoUs.
Delhi: 1.5T MRI & 16-slice CT scan at Janakpuri Super Speciality Hospital.
Uttar Pradesh: CT scan facilities across Muzaffarnagar, Bagpat, Amroha, Meerut, Agra, Noida, Lucknow, among others.
Nashik: Operation and maintenance of CT scan machines in partnership with Nashik Municipal Corporation.
Pathology:
Sample collection (home or center)
Sample transport to hub
Processing across departments (biochemistry, hematology, etc.)
Doctor’s review and report approval
EMR integration for online access
Radiology:
Patient transport (if required)
Scanning (MRI, CT, USG, etc.)
3D Image Reconstruction
Report generation by doctors
EMR integration for patient access
EBITDA margin increased from 9.95% in FY 2022–23 to 28.46% in FY 2023–24, and maintained at 27.53% in H1 FY 2024–25.
Growth attributed to:
Operating leverage improvement (revenue grew 34.5% in FY24 to ₹7,850.36 lakhs)
Cost rationalization (closure of 3 underperforming centres, 20% staff reduction)
Efficiency gains (automation and better resource allocation)
Consumable cost reduction from ~38% to ~32% of revenue
As of March 31 st, 2025, the Company has 211 full time employees including executive directors. The Banker to the comapny is Standard Chartered Bank.
INDUSTRY ANALYSIS
Healthcare Industry in India: A Growing Powerhouse
The Indian healthcare sector is one of the country’s largest and fastest-growing industries, encompassing hospitals, pharmaceuticals, medical devices, diagnostics, telemedicine, health insurance, and medical tourism. This growth is driven by increased coverage, rising investments, and a surge in healthcare demand across urban and rural regions.
India’s healthcare system is split into two primary components:
The public sector, which provides basic healthcare services through Primary Health Centers (PHCs) in rural areas
The private sector, which delivers the bulk of secondary, tertiary, and quaternary care, particularly in metro and tier-I/tier-II cities
India holds a global edge with its highly qualified medical professionals and cost-effective services—surgical procedures in India are about one-tenth the cost compared to the US and Western Europe. This has positioned India as a top destination for medical tourism, with over 630,000 foreign medical tourists in 2023.
Market Size & Growth Dynamics
The Indian healthcare market was valued at $372 billion in 2023 and is expected to reach new heights, fueled by government schemes, digital health advancements, and infrastructure expansion. The hospital segment alone was worth $98.98 billion in 2023, projected to nearly double by 2032 at an 8% CAGR.
Telemedicine is emerging as a strong pillar, projected to hit $5.4 billion by 2025, while the e-health market is expected to touch $10.6 billion by the same year.
Medical tourism is growing rapidly, anticipated to grow from $7.69 billion in 2024 to $14.31 billion by 2029.
Meanwhile, government spending on healthcare rose to 1.9% of GDP in FY24, up from 1.6% in FY21.
On the education front, 60 new medical colleges were added in 2024, raising MBBS seats by 6.3% to over 1.15 lakh, reflecting efforts to address the doctor-patient ratio, which now stands at 1:854.
Diagnostics Industry: Backbone of Preventive Healthcare
The Indian diagnostics industry is witnessing robust growth. Between FY17 and FY24, the market expanded at a 9-10% CAGR, reaching approximately ₹1 trillion. It is now expected to grow at a 10-12% CAGR between FY24 and FY28, reaching a market size of ₹1.27–1.37 trillion.
This expansion is powered by:
Growing lifestyle diseases
Urbanization and higher disposable incomes
Preventive health check-up awareness
Technological innovation
Radiology is forecast to grow at a 11–13% CAGR, while pathology is projected at 9–11% CAGR during FY24–FY28. Despite this progress, rural India contributes just 24% to diagnostic revenues, highlighting a significant under-penetration.
Structural Shifts: From Standalone Labs to Diagnostic Chains
The Indian diagnostics space is highly fragmented, with diagnostic chains now accounting for 20-24% of the market, up from 13-17% in FY20. This shift was accelerated by the COVID-19 pandemic, which highlighted the need for reliable, scalable, and tech-enabled diagnostic services.
Organized diagnostic chains benefit from:
Operational scale and efficiency
Stronger financials
National accreditations (like NABL)
Home sample collections and digital reporting
Chains are expanding in tier-II and tier-III cities and engaging in M&A activity to consolidate their presence.
Public-Private Partnerships (PPP): Unlocking Rural Potential
To bridge rural healthcare gaps, the PPP model is gaining traction, wherein private diagnostic players collaborate with the government to deliver services at subsidized rates. With rural areas making up 70% of India’s population but only 24% of diagnostics revenue, there’s a huge untapped market.
PPP initiatives can offer:
Infrastructure support
Long-term concession agreements (10 years)
Technology and capital access to underserved regions
Key Growth Drivers
Aging population: Share of citizens aged 60+ is rising, driving demand for chronic illness diagnostics.
Government initiatives: Schemes like PMJAY, NHM, NUHM, and the Free Diagnostics Service Initiative have significantly improved access.
Health-tech boom: A surge in digital diagnostics, AI, virtual consultations, and home testing is expanding service reach.
Success Factors for Diagnostic Players
Success in diagnostics hinges on:
Comprehensive test menus
Pan-India presence
Brand trust and doctor networks
Strong logistics and shorter TATs
Omni-channel strategies
Captive hospital tie-ups
Affordable pricing in rural markets
High quality and accuracy in testing
NABL Accreditation
Profitability Trends and Competitive Landscape
In FY23, profitability declined due to rising digitization costs, reduced COVID testing revenue, and price competition from online players. However, FY24 saw a 10% recovery in revenues driven by increased patient volumes and higher realization per test.
Major players like Dr Lal PathLabs, Metropolis, Thyrocare, and Vijaya are focusing on:
Franchise expansion
Tier-II/III penetration
Digital transformation
Cost optimization
These diagnostic chains reported OPBDIT margins between 25-45% during their peak but are expected to maintain range-bound margins in FY25 due to price pressures and rising input costs.
Outlook
With a CAGR of 10-11% expected till FY28, India's healthcare sector is poised to become a trillion-dollar-plus ecosystem. Diagnostics, as the cornerstone of preventive and evidence-based medicine, will continue to attract investment, innovation, and policy support.
Rural penetration, technological disruption, and collaborations via PPPs will define the next phase of this transformative industry.
BUSINESS STRENGTHS
1. Accurate Diagnosis:
Star Imaging and Path Lab diagnostic centers are equipped with state-of-the-art technology and medical equipment, including MRI, CT scans, X-rays, and laboratory testing tools, facilitating precise and timely diagnosis.
2. Specialized Expertise:
The centers are staffed with qualified medical professionals who possess specialized knowledge in radiology, pathology, and laboratory sciences, ensuring high standards in testing and result interpretation.
3. Standardized Sample Handling:
All procedures for sample collection, handling, and processing—covering blood, urine, and tissue samples—are well-defined and standardized. This ensures optimal sample integrity, minimizes contamination risks, and supports accurate and reliable test outcomes.
BUSINESS STRATEGIES
1. Nationwide Network Expansion:
Star Imaging and Path Lab aims to strengthen its footprint across India by increasing the number of diagnostic centres and services, particularly in regions where the company already operates. The expansion strategy focuses on leveraging operational expertise to scale across all states, including Tier II and Tier III cities. Key growth enablers include competitive pricing, consistent accuracy in diagnostic results, efficient service delivery—such as tele-reporting—and strategic brand-building efforts, all designed to attract a broader customer base.
2. Broadened Diagnostic Service Portfolio with Emphasis on Specialized Testing:
Future plans include enhancing capabilities in advanced diagnostic segments, particularly molecular diagnostics and genomics. The company plans to utilize its presence across multiple states, along with its extensive infrastructure, to introduce additional diagnostic services. At locations currently offering radiology, there are plans to integrate pathology services, expanding into areas such as healthcare screenings, chronic disease monitoring, and lifestyle-related diagnostics. Additional value-added offerings are also being considered, such as home specimen collection, home delivery of reports, and improved customer support services.
BUSINESS RISK FACTORS & CONCERNS
1. Dependence on Third-Party Vendors
Significant reliance on third-party vendors and suppliers for testing equipment, kits, and reagents poses a risk. Supply chain disruptions or recalls can materially impact operations and financial performance.
2. Reliance on Brand Image and Disposable Income of Patients
Major revenue generation depends on individual patients (B2C segment), making brand recognition, reputation, patient income levels, and public health awareness critical to business sustainability.
3. Risk from Non-Renewal of Institutional Contracts
Termination or non-renewal of agreements with institutional clients, including hospitals and PPP arrangements, may adversely affect revenues and operational stability. As of March 31, 2025, 20 centers were operated under the PPP model.
4. Geographical Revenue Concentration
100% of revenue from operations in FY25 was derived from Delhi and Uttar Pradesh. Any regional disruption in these states could significantly impact business performance.
Summary:
Star Imaging and Path Lab’s business faces key risks including overdependence on third-party suppliers, reliance on brand and patient spending, vulnerability to institutional contract changes, and geographical concentration of revenue. These factors may materially impact financial and operational outcomes if not managed effectively.
| Period Ended | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|
| Reserve of Surplus | 3,365.67 | 2,985.14 | 1,743.38 |
| Total Assets | 9,815.65 | 8,163.50 | 6,123.07 |
| Total Borrowings | 3,273.42 | 3,063.74 | 3,226.13 |
| Fixed Assets | 2,091.12 | 2,170.16 | 1,341.47 |
| Cash | 534.64 | 1,571.40 | 235.37 |
| Net Borrowing | 2,738.78 | 1,492.34 | 2,990.76 |
| Revenue | 8,378.74 | 7,997.42 | 5,868.18 |
| EBITDA | 2,888.88 | 2,364.67 | 597.07 |
| PAT | 1,595.54 | 1,245.38 | 58.29 |
| EPS | 11.8 | 9.2 | 0.43 |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Key Performance Indicator |
|||||||||||
| KPI | Values | ||||||||||
| EPS Pre IPO (Rs.) | ₹ 11.8 | ||||||||||
| EPS Post IPO (Rs.) | ₹ 9.16 | ||||||||||
| P/E Pre IPO | 12.03 | ||||||||||
| P/E Post IPO | 15.50 | ||||||||||
| ROE | 41.00 % | ||||||||||
| ROCE | 29.92 % | ||||||||||
| P/BV | 4.07 | ||||||||||
| Debt/Equity | 0.69 | ||||||||||
| RoNW | 40.65 % | ||||||||||
Star Imaging and Path Lab Limited IPO Peer Comparison |
|||||||||||
| Company Name | EPS | ROCE | ROE | P/E (x) | P/Bv | Debt/Equity | RoNW (%) | ||||
| Star Imaging and Path Lab Limited | ₹ 9.16 | 29.92 % | 41.00 % | 15.50 | 4.07 | 0.69 | 40.65 % | ||||
| Chandan Healthcare Limited | ₹ 9.07 | 28.1 % | 27.1 % | 28.3 | 5.12 | 0.39 | 27.1 % | ||||
| Vijaya Diagnostic Centre Limited | ₹ 14.6 | 21.7 % | 19.8 % | 73.0 | 13.8 | 0.40 | 19.8 % | ||||
| Metropolis Healthcare Limited | ₹ 28.0 | 14.7 % | 11.5 % | 75.3 | 7.90 | 0.15 | 11.5 % | ||||
STAR IMAGING AND PATH LAB LIMITED
4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi- 110018, India
Contact Person : Md Shadab Khan
Telephone : +91 9990019189
Email : cs@starimaging.in
Website : https://www.starimaging.in/
Registrar : KFIN TECHNOLOGIES LIMITED
Contact Person : Mr. Murali Krishna
Telephone : +91 40 6716 2222/18003094001
Email : sipll.ipo@kfintech.com
Website : https://www.kfintech.com/
Lead Manager : SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED
Contact Person : Mr. Kunal Bansal
Telephone : +91-120-4910000
Email : kunal.bansal@shareindia.co.in
Website : https://www.shareindia.com/
Star Imaging Path Lab Limited was conceptualized as the high-tech wing of Janta X-Ray Clinic, which was established in 1978. Star Imaging Path Lab Limited is the ONLY diagnostic brand in the private sector across Delhi and NCR with over three decades of expertise in the healthcare domain. The brand’s unique selling propositions are its comprehensive services—offering Radiology, Pathology, Cardiology, and Neurology all under one roof—and its ability to cater to all three segments of the healthcare value chain: Panels, Referrals, and Preventive care.
The company is led by Promoters, MR. PAWAN GUPTA who has experience of 21 years in financial strategy and market analysis has fueled growth and sustainability through data-driven decisions and strategic partnerships’ and MS. CHHAYA GUPTA has experience of 7.5 years in Human Resource and operational activities of the Company.
The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 8,378.74 Lakh, ₹ 7,997.42 Lakh and ₹ 5,868.18 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 2,888.88 Lakh, ₹ 2,364.67 Lakh and ₹ 597.07 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,595.54 Lakh, ₹ 1,245.38 Lakh and ₹ 58.29 Lakh respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹ 11.8 and post-issue EPS of ₹ 9.16 for FY24. The pre-issue P/E ratio is 12.03x, while the post-issue P/E ratio is 15.50x. The company's ROCE for FY24 is 29.92%, ROE for FY24 is 41.00% and RoNW is 40.65%. These metrics suggest that the IPO is fully priced.
The Grey Market Premium (GMP) of Star Imaging and Path Lab showing listing gains of 12.67 %.Given the company's financial performance and the valuation of the IPO, we recommend Risky Investors to Apply to the Star Imaging and Path Lab Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms
Copyright @2020 Design & Developed by Info Web Software